EG-UC5T Linear Array Endoscope Receives CE Mark Reports SonoScape

On April 30th, SonoScape received the CE-marking, the product’s “Passport to Europe“, for its linear-array echoendoscope EG-UC5T. This further expands SonoScape’s endoscopic ultrasound (EUS) portfolio in the international market.

Reaping the benefits of decades of ultrasound technology know-how, SonoScape’s EUS product line officially debuted in September 2019, when its 360° radial-array echoendoscope EG-UR5 obtained the CE Marking, leaping to the 4th company in the world to master the core technology of EUS.

EG-UC5T is characterized by its large, 4.0-mm instrument channel and its short rigid distal end, pushing the boundaries of therapeutic excellence. With the arrival of the linear-array echoendoscope EG-UC5T, SonoScape users are not only able to perform the adequate tissue sampling, but also various therapeutic interventional endoscopic procedures under the sonographic guidance. This is a true “best of the two worlds”, a golden key to reveal what’s behind the GI tract mucosa and to unlock the growing possibilities of advanced endoscopy.

“SonoScape’s EUS portfolio will certainly extend the company’s path into more and larger hospitals. This again underpins the company’s leading role in the global digestive endoscopy market.” said Steven He, Sales Director of Endoscopy Division at SonoScape: “We have achieved great results with our current gastrointestinal endoscopes, and I am confident that the new linear-array echoendoscopes will set us to a higher success.”

The last 25 years have witnessed a major expansion of EUS to various applications, both diagnostic and therapeutic, as noted in Friedberg SR, Lachter J, World Journal of Gastrointestinal Endoscopy (2017).  Focused on delivering high quality products, SonoScape continues to bring significant value to the world of endoscopy.

 

SourceSonoScape

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version